oxytocin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| oxytocin derivatives | 2042 | 50-56-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 15 | U | N |
| 200 | U | O |
| 15 | U | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 12 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 17, 1980 | FDA | NOVARTIS |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Exposure during pregnancy | 873.17 | 33.28 | 361 | 4807 | 155186 | 63328668 |
| Maternal exposure during pregnancy | 565.52 | 33.28 | 298 | 4870 | 219764 | 63264090 |
| Postpartum haemorrhage | 386.38 | 33.28 | 75 | 5093 | 1906 | 63481948 |
| Maternal exposure during delivery | 381.57 | 33.28 | 71 | 5097 | 1429 | 63482425 |
| Premature delivery | 251.55 | 33.28 | 94 | 5074 | 30187 | 63453667 |
| Hypotension | 204.62 | 33.28 | 172 | 4996 | 272432 | 63211422 |
| Caesarean section | 202.44 | 33.28 | 69 | 5099 | 16963 | 63466891 |
| Uterine atony | 195.08 | 33.28 | 30 | 5138 | 174 | 63483680 |
| Normal newborn | 165.88 | 33.28 | 50 | 5118 | 8291 | 63475563 |
| Uterine rupture | 133.39 | 33.28 | 28 | 5140 | 1058 | 63482796 |
| Ventilation perfusion mismatch | 122.03 | 33.28 | 23 | 5145 | 495 | 63483359 |
| Pre-eclampsia | 112.37 | 33.28 | 38 | 5130 | 9095 | 63474759 |
| Premature baby | 94.84 | 33.28 | 42 | 5126 | 20693 | 63463161 |
| Foetal exposure during pregnancy | 91.81 | 33.28 | 47 | 5121 | 31915 | 63451939 |
| Electrocardiogram ST segment depression | 87.40 | 33.28 | 24 | 5144 | 2853 | 63481001 |
| Drug ineffective | 85.96 | 33.28 | 230 | 4938 | 1044535 | 62439319 |
| Anaphylactoid syndrome of pregnancy | 83.42 | 33.28 | 12 | 5156 | 40 | 63483814 |
| Anaphylactic reaction | 83.17 | 33.28 | 57 | 5111 | 66043 | 63417811 |
| Amniotic cavity infection | 80.31 | 33.28 | 19 | 5149 | 1244 | 63482610 |
| Low birth weight baby | 77.33 | 33.28 | 27 | 5141 | 7102 | 63476752 |
| Bradycardia foetal | 69.74 | 33.28 | 14 | 5154 | 422 | 63483432 |
| Hypoxia | 69.21 | 33.28 | 49 | 5119 | 59743 | 63424111 |
| Placenta accreta | 65.80 | 33.28 | 12 | 5156 | 214 | 63483640 |
| Premature rupture of membranes | 62.29 | 33.28 | 21 | 5147 | 4972 | 63478882 |
| Acute pulmonary oedema | 59.25 | 33.28 | 23 | 5145 | 8135 | 63475719 |
| Stillbirth | 56.10 | 33.28 | 21 | 5147 | 6729 | 63477125 |
| Small for dates baby | 55.72 | 33.28 | 18 | 5150 | 3733 | 63480121 |
| Tachycardia | 54.26 | 33.28 | 57 | 5111 | 118099 | 63365755 |
| Uterine haemorrhage | 50.42 | 33.28 | 17 | 5151 | 4024 | 63479830 |
| Pulmonary oedema | 50.09 | 33.28 | 39 | 5129 | 54834 | 63429020 |
| Retained placenta or membranes | 48.79 | 33.28 | 10 | 5158 | 335 | 63483519 |
| Uterine tachysystole | 48.73 | 33.28 | 7 | 5161 | 23 | 63483831 |
| Failed induction of labour | 48.37 | 33.28 | 10 | 5158 | 350 | 63483504 |
| Endometritis | 47.80 | 33.28 | 12 | 5156 | 1006 | 63482848 |
| Vascular resistance systemic decreased | 46.98 | 33.28 | 8 | 5160 | 94 | 63483760 |
| Fatigue | 44.93 | 33.28 | 9 | 5159 | 888019 | 62595835 |
| Uterine hypertonus | 44.22 | 33.28 | 9 | 5159 | 291 | 63483563 |
| Foetal death | 43.09 | 33.28 | 20 | 5148 | 10960 | 63472894 |
| Mean arterial pressure decreased | 42.99 | 33.28 | 8 | 5160 | 160 | 63483694 |
| Hypothermia | 41.97 | 33.28 | 21 | 5147 | 13560 | 63470294 |
| Gestational diabetes | 41.59 | 33.28 | 18 | 5150 | 8378 | 63475476 |
| Disseminated intravascular coagulation | 40.62 | 33.28 | 23 | 5145 | 19028 | 63464826 |
| Cardiac output increased | 40.49 | 33.28 | 8 | 5160 | 222 | 63483632 |
| Live birth | 39.23 | 33.28 | 25 | 5143 | 25605 | 63458249 |
| Stroke volume increased | 37.71 | 33.28 | 5 | 5163 | 7 | 63483847 |
| Premature labour | 37.66 | 33.28 | 19 | 5149 | 12485 | 63471369 |
| Gestational hypertension | 37.54 | 33.28 | 12 | 5156 | 2405 | 63481449 |
| Diarrhoea | 36.66 | 33.28 | 7 | 5161 | 715359 | 62768495 |
| Vaginal haemorrhage | 35.23 | 33.28 | 24 | 5144 | 27463 | 63456391 |
| Delivery | 34.85 | 33.28 | 10 | 5158 | 1393 | 63482461 |
| Foetal heart rate deceleration abnormality | 34.15 | 33.28 | 8 | 5160 | 501 | 63483353 |
| Polyhydramnios | 34.14 | 33.28 | 11 | 5157 | 2260 | 63481594 |
| Foetal growth restriction | 33.55 | 33.28 | 15 | 5153 | 7538 | 63476316 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Foetal exposure during pregnancy | 378.83 | 106.85 | 89 | 384 | 38012 | 34918446 |
| Premature baby | 204.21 | 106.85 | 48 | 425 | 19585 | 34936873 |
| Low birth weight baby | 117.66 | 106.85 | 26 | 447 | 7879 | 34948579 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Exposure during pregnancy | 814.80 | 36.87 | 275 | 4063 | 100857 | 79639193 |
| Maternal exposure during pregnancy | 723.05 | 36.87 | 272 | 4066 | 136266 | 79603784 |
| Postpartum haemorrhage | 372.45 | 36.87 | 66 | 4272 | 1529 | 79738521 |
| Maternal exposure during delivery | 363.25 | 36.87 | 63 | 4275 | 1283 | 79738767 |
| Premature delivery | 282.42 | 36.87 | 87 | 4251 | 23380 | 79716670 |
| Uterine atony | 202.28 | 36.87 | 29 | 4309 | 155 | 79739895 |
| Caesarean section | 200.78 | 36.87 | 58 | 4280 | 12477 | 79727573 |
| Normal newborn | 184.32 | 36.87 | 48 | 4290 | 7024 | 79733026 |
| Pre-eclampsia | 132.65 | 36.87 | 37 | 4301 | 7004 | 79733046 |
| Ventilation perfusion mismatch | 126.44 | 36.87 | 23 | 4315 | 617 | 79739433 |
| Uterine rupture | 104.77 | 36.87 | 20 | 4318 | 701 | 79739349 |
| Amniotic cavity infection | 89.93 | 36.87 | 18 | 4320 | 809 | 79739241 |
| Anaphylactoid syndrome of pregnancy | 89.21 | 36.87 | 12 | 4326 | 36 | 79740014 |
| Electrocardiogram ST segment depression | 84.44 | 36.87 | 24 | 4314 | 4854 | 79735196 |
| Hypotension | 79.43 | 36.87 | 108 | 4230 | 440209 | 79299841 |
| Premature rupture of membranes | 74.87 | 36.87 | 21 | 4317 | 4048 | 79736002 |
| Stillbirth | 66.39 | 36.87 | 19 | 4319 | 3936 | 79736114 |
| Anaphylactic reaction | 65.12 | 36.87 | 46 | 4292 | 83697 | 79656353 |
| Hypoxia | 62.98 | 36.87 | 49 | 4289 | 103194 | 79636856 |
| Uterine haemorrhage | 58.08 | 36.87 | 16 | 4322 | 2887 | 79737163 |
| Placenta accreta | 57.63 | 36.87 | 10 | 4328 | 203 | 79739847 |
| Acute pulmonary oedema | 55.84 | 36.87 | 23 | 4315 | 14207 | 79725843 |
| Endometritis | 55.38 | 36.87 | 12 | 4326 | 796 | 79739254 |
| Bradycardia foetal | 55.08 | 36.87 | 9 | 4329 | 125 | 79739925 |
| Retained placenta or membranes | 55.04 | 36.87 | 10 | 4328 | 266 | 79739784 |
| Gestational diabetes | 49.76 | 36.87 | 17 | 4321 | 6276 | 79733774 |
| Foetal death | 49.38 | 36.87 | 18 | 4320 | 8026 | 79732024 |
| Tachycardia | 48.77 | 36.87 | 54 | 4284 | 177714 | 79562336 |
| Premature labour | 48.64 | 36.87 | 18 | 4320 | 8372 | 79731678 |
| Drug ineffective | 47.41 | 36.87 | 147 | 4191 | 1080766 | 78659284 |
| Live birth | 46.65 | 36.87 | 22 | 4316 | 18722 | 79721328 |
| Vaginal haemorrhage | 46.42 | 36.87 | 23 | 4315 | 21794 | 79718256 |
| Vascular resistance systemic decreased | 43.88 | 36.87 | 8 | 4330 | 217 | 79739833 |
| Cardiac output increased | 42.25 | 36.87 | 8 | 4330 | 268 | 79739782 |
| Failed induction of labour | 41.99 | 36.87 | 8 | 4330 | 277 | 79739773 |
| Polyhydramnios | 41.54 | 36.87 | 11 | 4327 | 1709 | 79738341 |
| Pulmonary oedema | 41.44 | 36.87 | 36 | 4302 | 88218 | 79651832 |
| Gestational hypertension | 40.58 | 36.87 | 11 | 4327 | 1868 | 79738182 |
| Mean arterial pressure decreased | 39.65 | 36.87 | 8 | 4330 | 374 | 79739676 |
| Stroke volume increased | 38.61 | 36.87 | 5 | 4333 | 10 | 79740040 |
| Small for dates baby | 37.90 | 36.87 | 8 | 4330 | 468 | 79739582 |
| Hypothermia | 36.93 | 36.87 | 20 | 4318 | 22726 | 79717324 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G02AC01 | GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS UTEROTONICS Ergot alkaloids and oxytocin incl. analogues, in combination |
| ATC | H01BB02 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES POSTERIOR PITUITARY LOBE HORMONES Oxytocin and analogues |
| FDA CS | M0015703 | Oxytocin |
| FDA PE | N0000009705 | Increased Uterine Smooth Muscle Contraction or Tone |
| MeSH PA | D010120 | Oxytocics |
| MeSH PA | D012102 | Reproductive Control Agents |
| CHEBI has role | CHEBI:35620 | vasodilator agents |
| CHEBI has role | CHEBI:36063 | oxytocic agents |
| FDA EPC | N0000175828 | Oxytocic |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Postpartum hemorrhage | indication | 47821001 | |
| Incomplete miscarriage | indication | 156072005 | |
| Induction of labor | indication | 236958009 | |
| Pregnancy with abortive outcome | indication | 363681007 | |
| Placental Reserve Studies | off-label use | ||
| Multiple pregnancy | contraindication | 16356006 | |
| Grand multipara | contraindication | 18656007 | |
| Placenta previa | contraindication | 36813001 | DOID:11060 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Fetal distress | contraindication | 130955003 | |
| Deliveries by cesarean | contraindication | 200144004 | |
| Finding of malposition of fetus | contraindication | 289365005 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cats | Uterine contractor to precipitate and accelerate normal parturition and postpartum evacuation of uterine debris | Indication |
| Cats | Postoperatively following cesarean section to facilitate involution and resistance to the large inflow of blood | Indication |
| Cattle | Uterine contractor to precipitate and accelerate normal parturition and postpartum evacuation of uterine debris | Indication |
| Cattle | Postoperatively following cesarean section to facilitate involution and resistance to the large inflow of blood | Indication |
| Cattle | Contracts smooth muscle cells of the mammary gland for milk letdown | Indication |
| Dogs | Uterine contractor to precipitate and accelerate normal parturition and postpartum evacuation of uterine debris | Indication |
| Dogs | Postoperatively following cesarean section to facilitate involution and resistance to the large inflow of blood | Indication |
| Horses | Uterine contractor to precipitate and accelerate normal parturition and postpartum evacuation of uterine debris | Indication |
| Horses | Postoperatively following cesarean section to facilitate involution and resistance to the large inflow of blood | Indication |
| Sheep | Uterine contractor to precipitate and accelerate normal parturition and postpartum evacuation of uterine debris | Indication |
| Sheep | Postoperatively following cesarean section to facilitate involution and resistance to the large inflow of blood | Indication |
| Swine | Uterine contractor to precipitate and accelerate normal parturition and postpartum evacuation of uterine debris | Indication |
| Swine | Postoperatively following cesarean section to facilitate involution and resistance to the large inflow of blood | Indication |
| Swine | Contracts smooth muscle cells of the mammary gland for milk letdown | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Oxytocin Injection | Zoetis Inc. | 1 |
| Oxytocin (Label Under Distributors) | Bimeda Animal Health Limited | 1 |
| Oxytocin Injectable | Bimeda Animal Health Limited | 1 |
| PVL Oxytocin Injectable | Bimeda Animal Health Limited | 1 |
| Oxytocin Injection | Bimeda Animal Health Limited | 1 |
| Oxytocin Injection | Bimeda Animal Health Limited | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.65 | acidic |
| pKa2 | 12.47 | acidic |
| pKa3 | 12.94 | acidic |
| pKa4 | 13.18 | acidic |
| pKa5 | 13.47 | acidic |
| pKa6 | 13.7 | acidic |
| pKa7 | 13.89 | acidic |
| pKa8 | 6.4 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Oxytocin receptor | GPCR | AGONIST | Ki | 9.10 | CHEMBL | CHEMBL | |||
| Vasopressin V1b receptor | GPCR | EC50 | 6.35 | WOMBAT-PK | |||||
| Vasopressin V2 receptor | GPCR | EC50 | 6.10 | WOMBAT-PK | |||||
| Oxytocin-neurophysin 1 | Secreted | WOMBAT-PK | |||||||
| Vasopressin V1a receptor | GPCR | EC50 | 6.91 | WOMBAT-PK | |||||
| Oxytocin receptor | GPCR | Ki | 9.05 | CHEMBL | |||||
| Vasopressin V2 receptor | GPCR | Ki | 7.21 | CHEMBL | |||||
| Vasopressin V1a receptor | GPCR | AGONIST | Ki | 6.10 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 4018039 | VUID |
| N0000146381 | NUI |
| D00089 | KEGG_DRUG |
| 4018039 | VANDF |
| C0030095 | UMLSCUI |
| CHEBI:7872 | CHEBI |
| CHEMBL395429 | ChEMBL_ID |
| D010121 | MESH_DESCRIPTOR_UI |
| DB00107 | DRUGBANK_ID |
| 2174 | IUPHAR_LIGAND_ID |
| 1480 | INN_ID |
| 1JQS135EYN | UNII |
| 439302 | PUBCHEM_CID |
| 7824 | RXNORM |
| 4537 | MMSL |
| 5223 | MMSL |
| d00584 | MMSL |
| 001307 | NDDF |
| 112115002 | SNOMEDCT_US |
| 12369008 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9742 | INJECTION | 10 [USPU] | INTRAMUSCULAR | ANDA | 20 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9743 | INJECTION | 10 [USPU] | INTRAMUSCULAR | ANDA | 20 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6114 | INJECTION | 10 [USPU] | INTRAMUSCULAR | NDA | 20 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6115 | INJECTION | 10 [USPU] | INTRAMUSCULAR | NDA | 20 sections |
| Pitocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-116 | INJECTION | 10 [iU] | INTRAVENOUS | NDA | 22 sections |
| Pitocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-130 | INJECTION | 10 [iU] | INTRAVENOUS | NDA | 22 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-048 | INJECTION, SOLUTION | 10 [USPU] | INTRAVENOUS | unapproved drug other | 1 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-051 | INJECTION, SOLUTION | 2 [USPU] | INTRAVENOUS | unapproved drug other | |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-054 | INJECTION, SOLUTION | 30 [USPU] | INTRAVENOUS | unapproved drug other | |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-055 | INJECTION, SOLUTION | 30 [USPU] | INTRAVENOUS | unapproved drug other | |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-056 | INJECTION, SOLUTION | 15 [USPU] | INTRAVENOUS | unapproved drug other | 1 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-056 | INJECTION, SOLUTION | 30 [USPU] | INTRAVENOUS | unapproved drug other | 1 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-105 | INJECTION, SOLUTION | 2 [USPU] | INTRAVENOUS | unapproved drug other | |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-170 | INJECTION, SOLUTION | 30 [USPU] | INTRAVENOUS | unapproved drug other | |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-233 | INJECTION, SOLUTION | 20 [USPU] | INTRAVENOUS | unapproved drug other | 1 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-234 | INJECTION, SOLUTION | 30 [USPU] | INTRAVENOUS | unapproved drug other | 1 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-9584 | INJECTION, SOLUTION | 10 [USPU] | INTRAVENOUS | NDA | 12 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-9584 | INJECTION, SOLUTION | 10 [USPU] | INTRAVENOUS | NDA | 12 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-012 | INJECTION, SOLUTION | 10 [USPU] | INTRAVENOUS | NDA | 12 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-012 | INJECTION, SOLUTION | 10 [USPU] | INTRAVENOUS | NDA | 12 sections |